Cellectar Biosciences, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
Mailing Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
Phone
(608) 441-8120
Fiscal Year End
1231
EIN
043321804
Financial Overview
FY2025
-$21.79M
Net Income
$9.80M
Total Liabilities
$-8.35
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 4, 2026 | View on SEC |
| 10-K Annual financial report | March 4, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 10, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | December 16, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | November 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
| S-1 IPO registration statement | October 20, 2025 | View on SEC |
Annual Reports
10-K
March 4, 2026
- PCLX-001, their lead product candidate, successfully completed patient enrollment for its Phase 2b DLBCL trial, a critical operational milestone.
- Received FDA Orphan Drug Designation for PCLX-001 for a specific rare cancer indication, offering potential market exclusivity and development incentives.
Insider Trading
SELL
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.